Ascend Capital’s Acceleron Pharma XLRN Stock Holding History

Ascend Capital’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-63,000	Closed	-$2.17M	–	225
2014 Q1	$2.17M	Buy	+63,000	New	+$2.84M	0.06%	169

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PVMCI

Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ascend Capital's XLRN Position: Q2 2014 in Review

Ascend Capital sold out of Acceleron Pharma (XLRN) in Q2 2014, closing a stake of 63,000 shares — an estimated $2.17M sold.

Ascend Capital first reported a position in XLRN in Q1 2014 and held it in 1 quarter. The position peaked at $2.17M in Q1 2014. 91 funds tracked by Wall St. Rank hold XLRN as of Q2 2014.

Ascend Capital reported no remaining Acceleron Pharma position as of Q2 2014 after selling out during the quarter.
Ascend Capital sold 63,000 Acceleron Pharma shares in Q2 2014, an estimated $2.17M.
Ascend Capital first reported a position in Acceleron Pharma in Q1 2014 and held it in 1 quarter.
Ascend Capital's Acceleron Pharma position peaked at $2.17M in Q1 2014.
91 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2014.

Based on Ascend Capital's 13F filing for Q2 2014, filed 13 Aug 2014.